rex.fit vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Zurich AI wearable camera with computer vision for automatic food nutrition logging; YC W23-backed with $450K revenue and $93K+ DROP preorders for Q4 2025 competing for automated fitness nutrition tracking.
About
rex.fit is a Zürich-based fitness technology company building The DROP — an AI-powered wearable camera that uses computer vision to automatically log food nutrition by photographing meals, track workouts, and generate gamified fitness challenges for health-conscious consumers who want data-driven fitness without manual calorie logging. Founded in 2023 by Ahmad Roumie and Rangel Milushev and backed by Y Combinator (W23), rex.fit generated $450,000 in revenue with a 2-person team and launched The DROP ($199 USD) with $93,000+ in pre-orders (approximately 450 units) targeted for Q4 2025 shipment, establishing a novel computer-vision food tracking wearable in a category dominated by wrist-based fitness trackers.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.